Researchers published a Nature Communications study showing a combination of bacteriophages and antibiotics effectively treated refractory peritoneal dialysis‑related peritonitis caused by Klebsiella pneumoniae. The work, led by Yang, Wu, and Jiang, demonstrated that phage‑antibiotic synergy can clear infections that resist standard therapies. The study provides preclinical evidence supporting adjunctive phage therapy for severe, device‑associated infections and may accelerate clinical trial interest in phage–antibiotic regimens. Developers and clinicians will evaluate scalability, regulatory pathways, and manufacturing controls needed to translate phage combinations into regulated therapeutics.